Product How it works Pricing Blog FAQ About Contact
Arbutus Biopharma

Arbutus Biopharma (NASDAQ: ABUS) net income

Arbutus Biopharma reported a net loss of $33.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $69.9m. Earnings per share were −$0.17.

Fiscal 2025 is the highest of the 10 fiscal years on record for Arbutus Biopharma. It reported a loss in 10 of those 10 years.

Net income, in millions of US dollars-384.22016-84.42017-57.12018-153.72019-63.72020-76.22021-69.52022-72.82023-69.92024-33.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$33.5m—−237.9%−$0.17
2024−$69.9m—−1,133.0%−$0.38
2023−$72.8m—−401.6%−$0.44
2022−$69.5m—−178.0%−$0.46
2021−$76.2m—−693.9%−$0.83
2020−$63.7m—−922.0%−$1.00
2019−$153.7m—−2,557.4%—
2018−$57.1m—−959.8%−$1.21
2017−$84.4m—−788.9%−$1.56
2016−$384.2m—−25,765.5%−$7.24

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Arbutus Biopharma net income compared with its sector

By net income for its latest fiscal year, Arbutus Biopharma ranks 226th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Arbutus Biopharma, −237.9%.

RankCompanyNet incomeNet margin
224thGalectin Therapeutics−$30.8m—
225thDiaMedica Therapeutics−$32.8m—
226thArbutus Biopharma−$33.5m−237.9%
227thAN2 Therapeutics−$35.2m—
228thImmunocore−$35.5m−8.9%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Arbutus Biopharma

How much did Arbutus Biopharma earn in fiscal 2025?
Arbutus Biopharma reported a net loss of $33.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $69.9m.
What are the earnings per share of Arbutus Biopharma?
They were −$0.17 in fiscal 2025, compared with −$0.38 in fiscal 2024.
Where does Arbutus Biopharma rank in its sector by net income?
It ranks 226th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Arbutus Biopharma come from?
From the annual report (Form 10-K) that Arbutus Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Arbutus Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Arbutus Biopharma: the Arbutus Biopharma page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.